ASTRAZENECA PLC DL-25/ GB0009895292 /
02/10/2024 07:57:05 | Chg. +1.8000 | Volume | Bid20:32:36 | Ask20:32:36 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
141.9000EUR | +1.28% | - Turnover: - |
143.2000Bid Size: 60 | 143.8500Ask Size: 60 | 222.49 bill.EUR | - | - |
GlobeNewswire
12/08
Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune...
GlobeNewswire
08/08
Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets...
GlobeNewswire
26/06
As the PNH Market Continues to Crowd, Spherix Announces New Suite of Advisory Services to Explore Co...
GlobeNewswire
20/06
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Gr...
GlobeNewswire
18/06
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
13/06
Rheumatologists' Aggressive Approach to SLE Treatment Targets Specific Patient Types with Biologics
GlobeNewswire
08/05
Annual NMDP Gala in New York Raises More Than $560,000, Enabling More Patients to Receive Life-Savin...
GlobeNewswire
08/05
Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Bi...
GlobeNewswire
06/05
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
GlobeNewswire
01/04
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent ...
GlobeNewswire
28/03
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Pati...